Search results
Results From The WOW.Com Content Network
According to the FDA, sotalol should not be used in people with a waking heart rate lower than 50 beats per minute. [8] It should not be used in people with sick sinus syndrome, long QT syndrome, cardiogenic shock, uncontrolled heart failure, asthma or a related bronchospastic condition, or people with serum potassium below 4 meq/L. [8] It should only be used in people with a second and third ...
Potassium channel blockers exhibit reverse use-dependent prolongation of the action potential duration. Reverse use dependence is the effect where the efficacy of the drug is reduced after repeated use of the tissue. [11] This contrasts with (ordinary) use dependence, where the efficacy of the drug is increased after repeated use of the tissue.
K + channel blocker. Sotalol is also a beta blocker [5] Amiodarone has mostly Class III activity, but also I, II, & IV activity [6] Prevent paroxysmal atrial fibrillation [7] and haemodynamically stable ventricular tachycardia [8] (amiodarone) Treat atrial flutter and atrial fibrillation (ibutilide) Treat ventricular tachycardia and atrial ...
Group of pharmaceuticals that are used to suppress abnormally fast rhythms (tachycardias), such as atrial fibrillation, supraventricular tachycardia and ventricular tachycardia.
Also known as hERG. Encodes the α-subunit of the rapid delayed rectifier potassium channel K V 11.1 carrying the potassium current I Kr. [22] LQT3 603830: SCN5A: Encodes the α-subunit of the cardiac sodium channel Na V 1.5 carrying the sodium current I Na. [22] LQT4 600919: ANK2: Encodes Ankyrin B which anchors the ion channels in the cell.
This page was last edited on 10 February 2018, at 11:08 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Ibutilide differs from other class III antiarrhythmic agents in that it activates the slow, delayed inward sodium channels rather than inhibiting outward potassium channels. Sotalol. Sotalol has beta-blocking activity. Approximately 2 to 7 percent of patients taking at least 320 mg/day experience proarrhythmia, most often in the form of TdP. [5]
E-4031 blocks hERG-type potassium channels [5] [6] by binding to the open channels. [7] Its structural target within the hERG-channel is unclear, but some other methanesulfonanilide class III antiarrhythmic drugs are known to bind to the S6 domain or C-terminal of the hERG-channel.